Ironwood Pharma (IRWD) Misses Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
UPDATE: Credit Suisse Downgrades Ironwood Pharmaceuticals (IRWD) to Neutral
November 7, 2018 5:15 AM EST(Updated - November 7, 2018 7:56 AM EST)
(updated to add analyst comments)
Credit Suisse analyst Vamil Divan downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Outperform to Neutral with a price target of $14.00 (from $22.00) citing disappointing updates on key product Linzess and what... More
JPMorgan Downgrades Ironwood Pharmaceuticals (IRWD) to Underweight
November 7, 2018 5:10 AM ESTJPMorgan analyst Eric Joseph downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Underweight with a price target of $11.00 (from $20.00).
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $12.78 yesterday.
... More